home / stock / blph / blph news

BLPH News and Press, Bellerophon Therapeutics Inc. From 11/07/19

Stock Information
Company Name: Bellerophon Therapeutics Inc.
Stock Symbol: BLPH
Market: OTC
Website: bellerophon.com
Menu
BLPH BLPH Quote BLPH Short BLPH News BLPH Articles BLPH Message Board
Get BLPH Alerts

News, Short Squeeze, Breakout and More Instantly...
BLPH - Bellerophon Presents New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at Pulmonary Fibrosis Foundation Summit 2019

WARREN, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, is presenting data from Cohort 1 of its ongoing Phase 2/3 randomized, double-blind, placebo-c...
BLPH - Daily Insider Ratings Round Up 10/28/19

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

BLPH - Bellerophon Presents New Positive Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting

Results Presented in Late-Breaking Abstract as an Oral Presentation Presentation Will Also be Published in the Highlights from CHEST Special Edition WARREN, N.J., Oct. 23, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the ȁ...

BLPH - Bellerophon to Present New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting

Results to be Presented in Late-Breaking Abstract as an Oral Presentation Presentation Will Also be Published in the Highlights from CHEST Special Edition WARREN, N.J., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or ...
BLPH - Bellerophon's nitric oxide an Orphan Drug in U.S. for IPF

The FDA has granted Orphan Drug Designation to Bellerophon Therapeutics' (NASDAQ: BLPH ) nitric oxide for the treatment of Idiopathic Pulmonary Fibrosis (IPF). More news on: Bellerophon Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

BLPH - Bellerophon Receives Orphan Drug Designation for Nitric Oxide in the Treatment of Idiopathic Pulmonary Fibrosis

WARREN, N.J., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designat...

BLPH - Bellerophon to Present at the H.C. Wainwright 21st Annual Global Investment Conference

WARREN, N.J., Sept. 04, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, announced today that Fabian Tenenbaum, Chief Executive Officer, will present a corporate ove...
BLPH - Bellerophon Therapeutics EPS in-line

Bellerophon Therapeutics (NASDAQ: BLPH ): Q2 GAAP EPS of -$0.06 in-line. More news on: Bellerophon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

BLPH - Bellerophon Provides Business Update and Reports Second Quarter 2019 Financial Results

WARREN, N.J., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the three and six months ...

BLPH - Bellerophon Completes Enrollment in Cohort 2 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

WARREN, N.J., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it has completed enrollment for Cohort 2 of its ongoing Phase 2/3 random...
Previous 10 Next 10